about
Type I interferon: friend or foe?Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cellsRespiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.Getting "Inside" Type I IFNs: Type I IFNs in Intracellular Bacterial InfectionsImmune-mediated animal models of Tourette syndrome.Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO).Increased activity of indoleamine 2,3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function.Mechanism underlying defective interferon gamma-induced IDO expression in non-obese diabetic mouse fibroblastsHypoxia abrogates antichlamydial properties of IFN-γ in human fallopian tube cells in vitro and ex vivo.Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancerDifferences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential.Indoleamine 2,3-dioxygenase in human hematopoietic stem cell transplantation.Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation?Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype.Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of human dendritic cellsThe role of indoleamine 2,3-dioxygenase in LP-BPM5 murine retroviral disease progression.IDO: a double-edged sword for T(H)1/T(H)2 regulation.Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities.Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism.Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis.Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome.CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendritic cells that have ceased interleukin-12 expression.
P2860
Q28293186-DD98F572-E2BA-4126-8F62-2D651B04681CQ28588016-86E3F389-8034-4956-A0F8-82074AD7CEE1Q33591243-860FBF1F-40E2-4E0C-9B91-7AEAC572EA3BQ33655568-4AEC9172-609D-4587-9965-940A75D8A815Q33745451-F3F06BE8-40EC-4BFD-9842-B1B0B0A9C627Q33832055-C47D1487-1E04-467B-8C91-C74EA44BE175Q33928921-4B5CBE18-0B81-4BDC-8C2F-AD287B7ED521Q34291222-9CBE191F-03DA-4E21-B172-6B0BAB94D28BQ34320598-E5629192-B0F2-44FC-AC98-57AA907D4450Q34414152-E99BFF42-6CC7-43C9-AD95-BDF41A1FBEC0Q34720273-651199E5-F816-499C-95FA-DDB4A1A01F77Q35005881-BBAC236A-A380-40BF-8D7A-14BE861E89BAQ35366857-57F18061-0C90-4FAF-A74C-789C00A25FEEQ36202875-0ACA4659-E6C3-447C-8BEC-258B80AF88D1Q36213003-D190E839-BDBF-4FE5-B76A-8C255385CF55Q36610873-51D659E7-25E2-4250-97EB-F695A34315E0Q37116807-77989BFD-B6FA-4624-B18E-AD4CA7A68D87Q37281950-4BBF59B2-BCC1-4CC7-9A2D-DABCBBA364E8Q37522460-C7743646-47D4-42DD-AC65-253E267B6C4CQ37671216-F7383B9A-AC6F-4629-B54C-4498573293BAQ38675915-8D1C1C80-F3E6-4A97-8B78-F98D1075CD54Q39532160-77537EAE-C3AC-4497-BCF6-DF4D04E55F15Q42040648-48A6ADB9-7C4F-4A49-8F8C-2D6B74FC70CBQ42378527-976B1E05-BADC-4657-A020-9467FE38E406Q43279107-738EBD04-F2BC-43A2-81AD-D75F7D27C475Q44192289-2F1BB561-9AC3-4138-9A3A-B2020EF00983Q48098105-40EDDB34-CAC3-44DE-820E-D6D5E56E3CEBQ50670959-FCF04F1B-AE66-4E4E-82D5-97F31A65EC26Q50784127-9D8A4735-9A4D-44CF-906D-5D11C304806A
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
On watching the watchers: IDO and type I/II IFN
@ast
On watching the watchers: IDO and type I/II IFN
@en
On watching the watchers: IDO and type I/II IFN
@nl
type
label
On watching the watchers: IDO and type I/II IFN
@ast
On watching the watchers: IDO and type I/II IFN
@en
On watching the watchers: IDO and type I/II IFN
@nl
prefLabel
On watching the watchers: IDO and type I/II IFN
@ast
On watching the watchers: IDO and type I/II IFN
@en
On watching the watchers: IDO and type I/II IFN
@nl
P2860
P356
P1476
On watching the watchers: IDO and type I/II IFN
@en
P2093
Paolo Puccetti
P2860
P304
P356
10.1002/EJI.200737184
P407
P577
2007-04-01T00:00:00Z